Er Therapeutics Stock Performance

Er Therapeutics Relative Risk vs. Return Landscape

If you would invest  0.26  in Er Therapeutics on November 4, 2025 and sell it today you would lose (0.25) from holding Er Therapeutics or give up 96.15% of portfolio value over 90 days. Er Therapeutics is currently does not generate positive expected returns and assumes 12.3112% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than PNGM, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.Given the investment horizon of 90 days Er Therapeutics is expected to under-perform the market. In addition to that, the company is 16.56 times more volatile than its market benchmark. It trades about -0.13 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.09 per unit of volatility.

Er Therapeutics Target Price Odds to finish over Current Price

Given the investment horizon of 90 days Er Therapeutics has a beta of -36.88 indicating as returns on its benchmark rise, returns on holding Er Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Er Therapeutics is expected to outperform its benchmark. In addition to that Er Therapeutics has an alpha of 37.7005, implying that it can generate a 37.7 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).

Predictive Modules for Er Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Er Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Hype Prediction Low Estimated High 0.00 0.000061 12.31 Details

Intrinsic Valuation Low Real High 0.00 0.000096 12.31 Details

Bollinger Band Projection (param) Lower Middle Band Upper 0.0001 0.0001 0.0001 Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Er Therapeutics. Your research has to be compared to or analyzed against Er Therapeutics' peers to derive any actionable benefits. When done correctly, Er Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Er Therapeutics.

Er Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Er Therapeutics is not an exception. The market had few large corrections towards the Er Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Er Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Er Therapeutics within the framework of very fundamental risk indicators.

Er Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Er Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Er Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.

Er Therapeutics Fundamentals Growth

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Will Diversified Metals & Mining sector continue expanding? Could PNGM diversify its offerings? Factors like these will boost the valuation of Er Therapeutics. Anticipated expansion of PNGM directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Er Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Investors evaluate Er Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Er Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Er Therapeutics' market price to deviate significantly from intrinsic value.

It's important to distinguish between Er Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Er Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Er Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.